dr. kluger on the toxicity profile of concurrent nivolumab and ipilimumab
Published 9 years ago • 244 plays • Length 1:45Download video MP4
Download video MP3
Similar videos
-
1:30
dr. kluger on toxicity of nivolumab/ ipilimumab for advanced melanoma
-
0:46
dr. kluger on a phase i trial of concurrent nivolumab and ipilimumab for advanced melanoma
-
2:10
dr. weber on the toxicity profile of nivolumab versus ipilimumab for melanoma
-
1:27
dr. kluger on how immunotherapies are changing the treatment of melanoma
-
1:37
dr. kluger on the changing landscape of immunotherapies for the treatment of melanoma
-
1:31
dr. kluger on toxicities associated with immunotherapies
-
1:03
dr. kluger on the difference between blocking pd-1 and pd-l1 in melanoma
-
1:28
dr. kluger on the changes and challenges of treating melanoma
-
1:59
dr. sznol on combining nivolumab and ipilimumab for the treatment of advanced melanoma
-
3:59
checkmate 067 - combined nivolumab and ipilimumab
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
1:34
dr. sharpless on managing toxicities with nivolumab/ipilimumab in melanoma
-
0:53
dr. rosenberg on dosing of nivolumab plus ipilimumab in bladder cancer
-
1:47
dr. sznol on combining nivolumab and ipilimumab for the treatment of advanced melanoma
-
0:49
krista rubin on understanding ipilimumab's toxicities
-
1:45
dr. tarhini compares two doses of ipilimumab
-
6:51
success for ipilimumab and nivolumab combo in advanced melanoma
-
1:29
dr. kelly on the toxicity profile in checkmate-227 in nsclc
-
1:04
the safety of nivolumab for advanced melanoma